Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Thomas Billiet, Isabelle Cleynen, Vera Ballet, Karolien Claes, Fred Princen, Sharat Singh, Marc Ferrante, Gert Van Assche, Ann Gils & Severine Vermeire. (2017) Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn’s disease. Scandinavian Journal of Gastroenterology 52:10, pages 1086-1092.
Read now
Read now
Maciej Tarnowski, Agnieszka Paradowska-Gorycka, Ewa Dąbrowska-Zamojcin, Michal Czerewaty, Sylwia Słuczanowska-Głąbowska & Andrzej Pawlik. (2016) The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy. Expert Opinion on Drug Metabolism & Toxicology 12:1, pages 41-55.
Read now
Read now
Xi Xie, David Zhang, Jin-wei Chen, Jing Tian, Guang-hui Ling & Fen Li. (2014) Pharmacogenomics of biological treatment in rheumatoid arthritis. Expert Opinion on Biological Therapy 14:2, pages 157-164.
Read now
Read now
Zhen Zeng, Zhenhua Duan, Tianchen Zhang, Sheng Wang, Guixing Li, Jing Gao, Dongqing Ye, Shengqian Xu, Jianhua Xu, Li Zhang & Faming Pan. (2013) Association between tumor necrosis factor-α (TNF-α) promoter −308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis. Modern Rheumatology 23:3, pages 489-495.
Read now
Read now
Maša Umićević Mirkov & Marieke JH Coenen. (2013) Pharmacogenetics of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: Towards Personalized Medicine. Pharmacogenomics 14:4, pages 425-444.
Read now
Read now
Rita Prajapati, Darren Plant & Anne Barton. (2011) Genetic and Genomic Predictors of Anti-TNF Response. Pharmacogenomics 12:11, pages 1571-1585.
Read now
Read now
Christian Grimstein & Jane PF Bai. (2011) Individualizing Therapy of Monoclonal Antibodies and Fusion Proteins: Emerging Potential in the Age of Personalized Medicine. Therapeutic Delivery 2:3, pages 369-381.
Read now
Read now
Marieke JH Coenen, Erik JM Toonen, Hans Scheffer, Timothy RDJ Radstake, Pilar Barrera & Barbara Franke. (2007) Pharmacogenetics of Anti-TNF Treatment in Patients with Rheumatoid Arthritis. Pharmacogenomics 8:7, pages 761-773.
Read now
Read now
Barbara Tolusso, Donatello Pietrapertosa, Alessia Morelli, Maria De Santis, Elisa Gremese, Giuseppina Farina, Siro Giorgio Carniello, Marino Del Frate & Gianfranco Ferraccioli. (2006)
IL-1B and IL-1RN Gene Polymorphisms in Rheumatoid Arthritis: Relationship with Protein Plasma Levels and Response to Therapy. Pharmacogenomics 7:5, pages 683-695.
Read now
Read now
Atsuo Taniguchi, Hisashi Yamanaka & Naoyuki Kamatani. (2006) Pharmacogenomics in the Treatment of Rheumatoid Arthritis: Clinical Implication and Perspective. Personalized Medicine 3:2, pages 151-163.
Read now
Read now
M. Cuchacovich, L. Soto, M. Edwardes, M. Gutierrez, C. Llanos, D. Pacheco, F. Sabugo, M. Alamo, C. Fuentealba, L. Villanueva, H. Gatica, I. Schiattino, L. Salazar, D. Catalan, O. Valenzuela, F. Salazar‐Onfray & J. C. Aguillón. (2006) Tumour necrosis factor (TNF)α −308 G/G promoter polymorphism and TNFα levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology 35:6, pages 435-440.
Read now
Read now
Prabha Ranganathan. (2005) Pharmacogenomics of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis. Pharmacogenomics 6:5, pages 481-490.
Read now
Read now
Articles from other publishers (42)
Sung Ho Lim, Khangyoo Kim & Chang-Ik Choi. (2022) Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis. Journal of Personalized Medicine 12:8, pages 1265.
Crossref
Crossref
Atinuke Aluko & Prabha Ranganathan. 2022. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
527
567
.
Koji Kimura, Atsushi Yoshida, Fumihiko Katagiri, Risa Takayanagi & Yasuhiko Yamada. (2019) Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling. Biopharmaceutics & Drug Disposition 40:7, pages 250-261.
Crossref
Crossref
Xia Jiang, Johan Askling, Saedis Saevarsdottir, Leonid Padyukov, Lars Alfredsson, Sebastien Viatte & Thomas Frisell. (2016) A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study. Arthritis Research & Therapy 18:1.
Crossref
Crossref
Dayse Celia Aroucha, Rodrigo Feliciano Carmo, Luydson Richardson Silva Vasconcelos, Raul Emidio Lima, Taciana Furtado Mendonça, Lucia Elena Arnez, Maria do Socorro Mendonça Cavalcanti, Maria Tereza Cartaxo Muniz, Marcilio Lins Aroucha, Erika Rabelo Siqueira, Luciano Beltrão Pereira, Patrícia Moura, Leila Maria Moreira Beltrão Pereira & Maria Rosangela Coêlho. (2016)
TNF‐α
and
IL‐10
polymorphisms increase the risk to hepatocellular carcinoma in HCV infected individuals
. Journal of Medical Virology 88:9, pages 1587-1595.
Crossref
Crossref
Tamer A. Gheita, Ghada S. Azkalany, Wafaa Gaber & Abeer Mohey. (2015) Clinical significance of serum TNFα and -308 G/A promoter polymorphism in rheumatoid arthritis. The Egyptian Rheumatologist 37:2, pages 49-54.
Crossref
Crossref
Miguel Cuchacovich, Daniel Bueno, Rodrigo Carvajal, Nicolás Bravo, Juan Carlos Aguillón, Diego Catalán & Lilian Soto. (2014) Clinical parameters and biomarkers for anti-TNF treatment prognosis in rheumatoid arthritis patients. Clinical Rheumatology 33:12, pages 1707-1714.
Crossref
Crossref
Jisna R Paul, Deepali Sen & Prabha Ranganathan. 2014. Handbook of Pharmacogenomics and Stratified Medicine. Handbook of Pharmacogenomics and Stratified Medicine
653
681
.
Deepali Sen, Jisna R. Paul & Prabha Ranganathan. 2014. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
625
660
.
E. Gallo, T. Cabaleiro, M. Román, G. Solano-López, F. Abad-Santos, A. García-Díez & E. Daudén. (2013)
The relationship between tumour necrosis factor (TNF)-α promoter and
IL12B
/
IL-23R
genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study
. British Journal of Dermatology 169:4, pages 819-829.
Crossref
Crossref
Melvin George, Sandhiya Selvarajan & Suresh Kumar Srinivasamurthy. 2013. Omics for Personalized Medicine. Omics for Personalized Medicine
249
262
.
E. Gallo, T. Cabaleiro, M. Román, F. Abad-Santos & E. Daudén. (2012) Study of Genetic Polymorphisms in the Tumor Necrosis Factor α Promoter Region in Spanish Patients With Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 103:4, pages 301-307.
Crossref
Crossref
E. Gallo, T. Cabaleiro, M. Román, F. Abad-Santos & E. Daudén. (2012) Estudio de los polimorfismos genéticos de la región promotora del TNF-α en pacientes españoles afectos de psoriasis. Actas Dermo-Sifiliográficas 103:4, pages 301-307.
Crossref
Crossref
Robert M. Plenge, Yvonne C Lee, Soumya Raychaudhuri & Daniel H. Solomon. 2012. Principles of Pharmacogenetics and Pharmacogenomics. Principles of Pharmacogenetics and Pharmacogenomics
188
201
.
Philippe Dieudé & Henri-Jean Garchon. (2011) Les applications en rhumatologie: en génomique. Revue du Rhumatisme 78, pages S178-S181.
Crossref
Crossref
Carlo Perricone, Fulvia Ceccarelli & Guido Valesini. (2011) An overview on the genetic of rheumatoid arthritis: A never-ending story. Autoimmunity Reviews 10:10, pages 599-608.
Crossref
Crossref
Francesca Ingegnoli, Ennio Giulio Favalli & Pier Luigi Meroni. (2011) Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature. Autoimmunity Reviews 10:8, pages 460-463.
Crossref
Crossref
Hans U Scherer, Thomas Dörner & Gerd R Burmester. (2010) Patient-tailored therapy in rheumatoid arthritis: an editorial review. Current Opinion in Rheumatology 22:3, pages 237-245.
Crossref
Crossref
YOUNG HO LEE, JONG DAE JI, SANG-CHEOL BAE & GWAN GYU SONG. (2010) Associations Between Tumor Necrosis Factor-α (TNF-α) −308 and −238 G/A Polymorphisms and Shared Epitope Status and Responsiveness to TNF-α Blockers in Rheumatoid Arthritis: A Metaanalysis Update. The Journal of Rheumatology 37:4, pages 740-746.
Crossref
Crossref
Ignacio Rego-Pérez, Mercedes Fernández-Moreno, Vanessa Carreira-García & Francisco J. Blanco. (2009) Polimorfismos genéticos y farmacogenética en la artritis reumatoide. Reumatología Clínica 5:6, pages 268-279.
Crossref
Crossref
C. Bansard, T. Lequerre, M. Daveau, O. Boyer, F. Tron, J.-P. Salier, O. Vittecoq & X. Le-Loet. (2009) Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?. Rheumatology 48:9, pages 1021-1028.
Crossref
Crossref
D D O'Rielly, N M Roslin, J Beyene, A Pope & P Rahman. (2009) TNF-α −308 G/A polymorphism and responsiveness to TNF-α blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. The Pharmacogenomics Journal 9:3, pages 161-167.
Crossref
Crossref
Ignacio Rego-Pérez, Mercedes Fernández-Moreno, Vanessa Carreira-García & Francisco J. Blanco. (2009) Gene polymorphisms and pharmacogenetics in rheumatoid arthritis. Reumatología Clínica (English Edition) 5:6, pages 268-279.
Crossref
Crossref
Dimitri Semizarov & Eric Blomme. 2008. Genomics in Drug Discovery and Development. Genomics in Drug Discovery and Development
329
383
.
Rolando Cimaz & Anne Marie Prieur. (2008) Advances in pediatric rheumatology. Future Rheumatology 3:3, pages 239-251.
Crossref
Crossref
Hubert Marotte, Béatrice Arnaud, Jennifer Diasparra, Saloua Zrioual & Pierre Miossec. (2008) Association between the level of circulating bioactive tumor necrosis factor α and the tumor necrosis factor α gene polymorphism at −308 in patients with rheumatoid arthritis treated with a tumor necrosis factor α inhibitor. Arthritis & Rheumatism 58:5, pages 1258-1263.
Crossref
Crossref
Sukhbir Singh Uppal, Raj Raghupathy, Sawsan J. Hayat, Rafiqul Islam Chowdhury, Mini Abraham & Parvez Rawoot. (2007) Patient demographics and disease variables correlate with distinct cytokine patterns in mitogen-stimulated peripheral blood mononuclear cells from rheumatoid arthritis patients. Rheumatology International 28:6, pages 533-539.
Crossref
Crossref
Robert M Plenge & Lindsey A Criswell. (2008) Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Current Opinion in Rheumatology 20:2, pages 145-152.
Crossref
Crossref
Liming Wang, Qiangrong Gu, Yan Xu, Shaohua Li, Jianchao Gui, Jianping Yang, Qingqiang Yao & Yong Ji. (2007)
EFFECTS OF YUNKE (TECHNETIUM‐99 CONJUGATED WITH METHYLENE DIPHOSPHONATE;
99
Tc‐MDP) AND/OR COLLOIDAL CHROMIC PHOSPHATE PHOSPHONIUM‐32, ALONE AND IN COMBINATION, IN RATS WITH ADJUVANT ARTHRITIS
. Clinical and Experimental Pharmacology and Physiology 35:1, pages 23-28.
Crossref
Crossref
D. J. Shealy & S. Visvanathan. 2008. Therapeutic Antibodies. Therapeutic Antibodies
101
129
.
Prabha Ranganathan. 2008. Pharmacogenomics in Drug Discovery and Development. Pharmacogenomics in Drug Discovery and Development
413
435
.
Mark C Fisher, Bruce N Cronstein & Jeffrey D Greenberg. (2007) Future treatment of rheumatic diseases: the role of pharmacogenetics. Future Rheumatology 2:6, pages 535-540.
Crossref
Crossref
E Lacaná, S Amur, P Mummanneni, H Zhao & F W Frueh. (2007) The Emerging Role of Pharmacogenomics in Biologics. Clinical Pharmacology & Therapeutics 82:4, pages 466-471.
Crossref
Crossref
G Ferraccioli, B Tolusso & M De Santis. (2006) Pharmacogenetic of antirheumatic treatments: clinical implications. The Pharmacogenomics Journal 7:1, pages 2-9.
Crossref
Crossref
Wouter M. Kooloos, Dirk J. de Jong, Tom W.J. Huizinga & Henk-Jan Guchelaar. (2007) Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discovery Today 12:3-4, pages 125-131.
Crossref
Crossref
Young Ho Lee, Young Hee Rho, Seong Jae Choi, Jong Dae Ji & Gwan Gyu Song. (2006) Association of TNF-alpha –308 G/A polymorphism with responsiveness to TNF-α-blockers in rheumatoid arthritis: a meta-analysis. Rheumatology International 27:2, pages 157-161.
Crossref
Crossref
Joanna Wesoly, Judith A. M. Wessels, Henk-Jan Guchelaar & Tom W. J. Huizinga. (2006) Genetic markers of treatment response in rheumatoid arthritis. Current Rheumatology Reports 8:5, pages 369-377.
Crossref
Crossref
Cecile Krejsa, Mark Rogge & Wolfgang Sadee. (2006) Protein therapeutics: new applications for pharmacogenetics. Nature Reviews Drug Discovery 5:6, pages 507-521.
Crossref
Crossref
Juan C. Aguillón, Andrea Cruzat, Octavio Aravena, Lorena Salazar, Carolina Llanos & Miguel Cuchacovich. (2006) Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution?. Immunobiology 211:1-2, pages 75-84.
Crossref
Crossref
Thierry Lequerré, Anne-Christine Gauthier-Jauneau, Carine Bansard, Céline Derambure, Martine Hiron, Olivier Vittecoq, Maryvonne Daveau, Othmane Mejjad, Alain Daragon, François Tron, Xavier Le Loët & Jean-Philippe Salier. (2006) Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Research & Therapy 8:4, pages R105.
Crossref
Crossref
Chris Deighton. (2006) The updated BSR guidelines for anti‐TNF in adults with RA: What has changed and why?. Musculoskeletal Care 3:3, pages 122-130.
Crossref
Crossref
Andreas Pascher & Jochen Klupp. (2005) Biologics in the Treatment of Transplant Rejection and Ischemia/Reperfusion Injury. BioDrugs 19:4, pages 211-231.
Crossref
Crossref